IDEAS home Printed from https://ideas.repec.org/p/chy/respap/113chedp.html
   My bibliography  Save this paper

Expenditure on the NHS during and after the Thatcher years: its growth and utilisation

Author

Listed:
  • Karen Bloor

    (Centre for Health Economics, The University of York)

  • Alan Maynard

    (Centre for Health Economics, The University of York)

Abstract

Has government expenditure on the National Health and Personal Social Services increased significantly in real terms over the past decade? If so, where has this growth in expenditure been utilised? This paper investigates claims of real increases in expenditure by examining trends in total expenditure on the NHS between 1979 and 1992, and disaggregating these trends to concentrate on different sectors, the influence of changes in NHS personnel, the revenue/capital split and the geographical distribution of expenditure increases. The total cost of the UK NHS has increased from approximately £9.2 billion in 1978/79 to £37.4 billion in 1991/92. Adjusting this figure to account for general inflation shows a real increase of 50.4% over this period. This gives a reflection of the increased cost of the NHS to the economy. However, adjusting the increases to account for changes in NHS pay and prices shows a smaller increase, of about 22% over the period, an average annual increase of around 1.5%. As NHS costs are taken into account, this measures what the NHS is able to buy with the increased resources. Increases in expenditure have not been evenly distributed between different sectors. The smallest relative increases have been in the hospital sector, which have absorbed a decreasing proportion of overall NHS and PSS expenditure over the period. The relative restriction on hospital budgets during the 1980s contributes greatly to the public perception of a parsimoniously funded health service. Expenditure on community health services has increased by the greatest proportion over the period, but this is still a small, though increasing, proportion of overall expenditure. The family health services budget (which funds primary care) has remained relatively stable as a proportion of overall expenditure over the 1980s. This means that significant real increases have taken place. This is due largely to increases in general practitioner and other staffing. Between 1980 and 1991, the number of GPs increased by around 19%, with average list sizes decreasing from 2,247 to 1,918. In addition, GPs have increasingly employed nursing and other support staff. There has also been increasing expenditure on pharmaceutical services (the government’s net expenditure on pharmaceuticals has increased by around 47% over the period 1778-79 to 1991-92). Finally, expenditure on personal social services has increased at around the same rate as overall health and PSS expenditure. The NHS is a labour intensive service, and this means that changes in personnel have major expenditure implications. Over the period studied, numbers of whole-time equivalent medical (particularly senior medical) and nursing staff increased steadily, and these staff received significant real increases in salary levels. There were also increases in the number of professional and technical staff and administrative and managerial staff. Numbers of whole-time equivalent administrative and clerical staff increased from 105,430 in 1980 to 129,716 in 1990, i.e. by around 23%. There were, however, significant reductions in numbers of directly employed works professional, maintenance and ancillary staff, due to government policies of contracting out these services. The resource consequences of the apparent shift towards relatively high paid staff are substantial, and if these trends continue the overall wage bill for the NHS will continue to increase considerably even if staff numbers do not. The majority of NHS expenditure is current expenditure, primarily on salaries and wages, with capital expenditure representing around 5-6% of total NHS expenditure in England over this period. Geographical distribution of hospital and community health services expenditure has also changed relatively little, despite the implementation of the RAWP formula for HCHS in England and similar formulae subsequently and elsewhere in the UK. No attempt has yet been made to equalise primary care spending using a RAWP-type allocation formula. This is surprising given the government’s emphasis on the integration of primary and secondary care and the primacy given to the services managed by general practitioners. The ‘Waiting List Initiative’ and more recent government pledges in the ‘Patients’ Charter’ were aimed at reducing waiting times, particularly the number of long waits, with guarantees that no one should wait more than two years for a procedure. This goal has been achieved but, as ever, supply creates demand in the absence of agreed clinical practice guidelines and the number waiting have, as a consequence, grown to over one million. This policy concentrates on activity, which is an unsuitable goal and an unusable measure of success. In allocating resources to the NHS, as in all other policy areas, the appropriate target should be efficiency. Increasing activity, where this activity is often of unproven effectiveness is inefficient and inappropriate. The level of public expenditure devoted to the National Health Service is largely a political decision – the overall budget, as in all other departments, is determined by the political bargaining of the annual public expenditure round. The settlement for 1994-95 includes a real funding increase and meets the 1992 Conservative election pledge, provided the Treasury estimates of inflation are correct (which is rare!) However, to achieve efficiency in the NHS, expenditure increases must be directed to areas of proven cost-effectiveness. This goal would be assisted by publication of more detailed breakdowns of NHS expenditure increases and more economic evaluation of new and existing health care programmes. In future there will be increasing pressure on limited NHS resources due to demographic change and technological advance. The vague ways in which NHS expenditure is monitored and “value for money” determined will have to be replaced by more sophisticated monitoring of spending and the provision of cost effectiveness data to ensure society’s scarce health care resources are used effectively. There is evidence of considerable scope to improve the efficiency of resource allocation in the NHS and this may be best achieved by the ‘leverage’ of parsimonious funding.

Suggested Citation

  • Karen Bloor & Alan Maynard, 1993. "Expenditure on the NHS during and after the Thatcher years: its growth and utilisation," Working Papers 113chedp, Centre for Health Economics, University of York.
  • Handle: RePEc:chy:respap:113chedp
    as

    Download full text from publisher

    File URL: http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20113.pdf
    File Function: First version, 1993
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Tony Scott & Alan Maynard, 1991. "Will the new GP contract lead to cost effective medical practice?," Working Papers 082chedp, Centre for Health Economics, University of York.
    2. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G. & Lasagna, Louis, 1991. "Cost of innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 10(2), pages 107-142, July.
    3. Roy Carr-Hill & Paul Dixon & Ian Gibbs & Mary Griffiths & Moira Higgins & Dorothy McMaughan & Ken Wright, 1992. "Skill mix and the effectiveness of nursing care," Working Papers 015cheop, Centre for Health Economics, University of York.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Richardson, Gerald & Maynard, Alan & Cullum, Nicky & Kindig, David, 1998. "Skill mix changes: substitution or service development?," Health Policy, Elsevier, vol. 45(2), pages 119-132, August.
    2. Gerald Richardson & Alan Maynard, 1995. "Fewer doctors? More nurses? A review of the knowledge base of doctor-nurse substitution," Working Papers 135chedp, Centre for Health Economics, University of York.
    3. J Mohan, 1995. "Post-Fordism and Welfare: An Analysis of Change in the British Health Sector," Environment and Planning A, , vol. 27(10), pages 1555-1576, October.
    4. Street, Andrew & Duckett, Stephen, 1996. "Are waiting lists inevitable?," Health Policy, Elsevier, vol. 36(1), pages 1-15, April.
    5. Karen Bloor & Alan Maynard & Andrew Street, 1999. "The cornerstone of Labour's 'New NHS': reforming primary care," Working Papers 168chedp, Centre for Health Economics, University of York.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Alan Maynard & Arthur Walker, 1993. "Planning the medical workforce: struggling out of the time warp," Working Papers 105chedp, Centre for Health Economics, University of York.
    2. Karen Bloor & Alan Maynard, 1995. "Equity in primary care," Working Papers 141chedp, Centre for Health Economics, University of York.
    3. Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
    4. Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
    5. Grabowski, Henry & Vernon, John & DiMasi, Joseph, 2002. "Returns on R&D for 1990s New Drug Introductions," Working Papers 02-21, Duke University, Department of Economics.
    6. Cardoso de Mendonca, Mario Jorge & Sachsida, Adolfo & Loureiro, Paulo R. A., 2003. "A study on the valuing of biodiversity: the case of three endangered species in Brazil," Ecological Economics, Elsevier, vol. 46(1), pages 9-18, August.
    7. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    8. Steven Casper;Hannah Kettler, 2000. "The Road to Sustainability in the UK and German Biotechnology Industries," Monograph 000466, Office of Health Economics.
    9. Schwartz, Eduardo S., 2002. "Patents and R& D as Real Options," University of California at Los Angeles, Anderson Graduate School of Management qt86b1n43k, Anderson Graduate School of Management, UCLA.
    10. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    11. Samira Guennif, 2007. "Global harmonisation of intellectual property rights and local impact. Patent and access to medicines in developing countries under TRIPS and TRIPS plus provisions [Harmonisation globale des systèm," Post-Print hal-01345869, HAL.
    12. Scherer, F. M., 2007. "Pharmaceutical Innovation," Working Paper Series rwp07-004, Harvard University, John F. Kennedy School of Government.
    13. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
    14. Mark Pauly & Kyle Myers, 2016. "A Ricardian-Demand Explanation for Changing Pharmaceutical R&D Productivity," NBER Working Papers 22720, National Bureau of Economic Research, Inc.
    15. Scott, Anthony & Hall, Jane, 1995. "Evaluating the effects of GP remuneration: problems and prospects," Health Policy, Elsevier, vol. 31(3), pages 183-195, March.
    16. Yin, Nina, 2023. "Pharmaceuticals, incremental innovation and market exclusivity," International Journal of Industrial Organization, Elsevier, vol. 87(C).
    17. Ming Ding & Jehoshua Eliashberg, 2002. "Structuring the New Product Development Pipeline," Management Science, INFORMS, vol. 48(3), pages 343-363, March.
    18. Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(3), pages 1049-1090.
    19. Patricia M. Danzon & Allison Percy, 1999. "The Effects of Price Regulation on Productivity in Pharmaceuticals," NBER Chapters, in: International and Interarea Comparisons of Income, Output, and Prices, pages 371-418, National Bureau of Economic Research, Inc.
    20. Natasha Palmer & Anne Mills, 2003. "Classical versus relational approaches to understanding controls on a contract with independent GPs in South Africa," Health Economics, John Wiley & Sons, Ltd., vol. 12(12), pages 1005-1020, December.

    More about this item

    Keywords

    expenditure;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:chy:respap:113chedp. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Gill Forder (email available below). General contact details of provider: https://edirc.repec.org/data/chyoruk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.